Roche Launches Elecsys Anti-p53 Immunoassay for In Vitro Quantitative Detection of Anti-p53 Antibodies to Aid Multi-Cancer Diagnosis

April 08, 2021 /BioValleyBIOON/ -- Roche recently announced the launch of Elecsys anti-p53Immunodiagnostic product for the quantitative in vitro determination of anti-p53 antibodies. This immunoassay product, in conjunction with other diagnostic tests, can be used to assist physiciansDiagnosisLaryngeal cancer, colorectal cancer,Breast CancerPatients. Currently, this immunoassay product is available in all markets that accept the CE mark.

Thomas Schinecker, CEO of Roche Diagnostics, stated: “Our Elecsys anti-p53 immunoassay will help clinicians rapidly and reliably diagnose several common cancers, potentially improving prognosis for many patients. In addition to groundbreaking cancer therapies, Roche offers a growing portfolio of diagnostic solutions to assist physicians”Diagnosisand the treatment of cancer patients.”

p53 is a protein that, when activated, helps regulate processes that prevent tumor development. p53 mutations are present in half of solidTumor, is by far the most common found in human cancersGeneticsAlterations. Certain p53 mutations can lead to the accumulation of p53, thereby inducing the formation of anti-p53 autoantibodies. Autoantibodies are antibodies produced by the body that mistakenly target and react with the body's own tissues. Anti-p53 autoantibodies are generated in 20–50% of patients with p53 mutations. This mutation converts the tumor-suppressive function of p53 into a tumor-promoting function, thereby contributing to cancer development.

AtTumorThe early appearance of anti-p53 antibodies during disease progression may have the potential to detect malignant changes. The Elecsys anti-p53 immunoassay can detect these anti-p53 antibodies, and when used in conjunction with other diagnostic tests, it can help facilitate earlyDiagnosisIn certain cancers, this may help improve patient prognosis. Determining the presence of anti-p53 antibodies may also aid in monitoring residual cancer cells remaining in the body after treatment. Furthermore, as part of cancer management, the Elecsys anti-p53 immunoassay can help identify which patients may be suitable for less invasive treatment procedures.(Bioon.com)

Original Source: Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types